Phase Ia/Ib Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors, including Pancreatic Cancer
The purpose of this phase I study is to evaluate the safety and efficacy of LY3537982 in patients with solid tumors, including pancreatic cancer expression KRAS G12C mutation.
Study ID: LOXO-RAS-20001
Trial Phase: Phase I
Trial Sponsor: Eli Lilly
Therapies Used in This Trial: LY3537982